Camille Adajar (Medicine) and Dr. Wolfram Samlowski of the Comprehensive Cancer Centers of Nevada recently published "Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy" in the journal BMC Cancer.

The article addresses patients with metastatic melanoma who progress after initial treatment with PD-1 or CTLA-4 directed antibodies and the urgent need for salvage options to decrease mortality in this population.